Inhibition of Serine Proteases As a Novel Therapeutic Strategy for Abdominal Pain in IBS

Overview

Journal Front Physiol

Date 2022 Jun 6

PMID 35665224

Authors

Lisse Decraecker

Guy Boeckxstaens

Alexandre Denadai-Souza

Affiliations

Soon will be listed here.

Abstract

Serine proteases are heavily present in the gastrointestinal tract where they are essential in numerous physiological processes. An imbalance in the proteolytic activity is a central mechanism underlying abdominal pain in irritable bowel syndrome (IBS). Therefore, protease inhibitors are emerging as a promising therapeutic tool to manage abdominal pain in this functional gastrointestinal disorder. With this review, we provide an up-to-date overview of the implications of serine proteases in the development of abdominal pain in IBS, along with a critical assessment of the current developments and prospects of protease inhibitors as a therapeutic tool. In particular, we highlight the current knowledge gap concerning the identity of dysregulated serine proteases that are released by the rectal mucosa of IBS patients. Finally, we suggest a workflow with state-of-the-art techniques that will help address the knowledge gap, guiding future research towards the development of more effective and selective protease inhibitors to manage abdominal pain in IBS.

Citing Articles

Beyond the "Master" Role in Allergy: Insights into Intestinal Mast Cell Plasticity and Gastrointestinal Diseases.

Molfetta R, Carnevale A, Marangio C, Putro E, Paolini R Biomedicines. 2025; 13(2).

PMID: 40002733 PMC: 11853218. DOI: 10.3390/biomedicines13020320.

Mast cell modulation: A novel therapeutic strategy for abdominal pain in irritable bowel syndrome.

Van Remoortel S, Hussein H, Boeckxstaens G Cell Rep Med. 2024; 5(10):101780.

PMID: 39378882 PMC: 11513802. DOI: 10.1016/j.xcrm.2024.101780.

Fecal Proteolytic Bacteria and Staphylococcal Superantigens Are Associated With Abdominal Pain Severity in Irritable Bowel Syndrome.

Quan R, Decraecker L, Appeltans I, Cuende-Estevez M, Van Remoortel S, Aguilera-Lizarraga J Am J Gastroenterol. 2024; 120(3):603-613.

PMID: 39166748 PMC: 11864055. DOI: 10.14309/ajg.0000000000003042.

Proteases and Their Potential Role as Biomarkers and Drug Targets in Dry Eye Disease and Ocular Surface Dysfunction.

Ramos-Llorca A, Scarpellini C, Augustyns K Int J Mol Sci. 2022; 23(17).

PMID: 36077189 PMC: 9456293. DOI: 10.3390/ijms23179795.

References

Flacco M, Manzoli L, De Giorgio R, Gasbarrini A, Cicchetti A, Bravi F . Costs of irritable bowel syndrome in European countries with universal healthcare coverage: a meta-analysis. Eur Rev Med Pharmacol Sci. 2019; 23(7):2986-3000. DOI: 10.26355/eurrev_201904_17580. View

Tooth D, Garsed K, Singh G, Marciani L, Lam C, Fordham I . Characterisation of faecal protease activity in irritable bowel syndrome with diarrhoea: origin and effect of gut transit. Gut. 2013; 63(5):753-60. PMC: 3995279. DOI: 10.1136/gutjnl-2012-304042. View

Caberoy N, Alvarado G, Li W . Identification of calpain substrates by ORF phage display. Molecules. 2011; 16(2):1739-48. PMC: 3175615. DOI: 10.3390/molecules16021739. View

Denadai-Souza A, Bonnart C, Sola Tapias N, Marcellin M, Gilmore B, Alric L . Functional Proteomic Profiling of Secreted Serine Proteases in Health and Inflammatory Bowel Disease. Sci Rep. 2018; 8(1):7834. PMC: 5959920. DOI: 10.1038/s41598-018-26282-y. View

Zhao J, Dong L, Shi H, Wang Z, Shi H, Ding H . The expression of protease-activated receptor 2 and 4 in the colon of irritable bowel syndrome patients. Dig Dis Sci. 2011; 57(1):58-64. DOI: 10.1007/s10620-011-1827-3. View

Martin L, Auge C, Boue J, Buresi M, Chapman K, Asfaha S . Thrombin receptor: An endogenous inhibitor of inflammatory pain, activating opioid pathways. Pain. 2009; 146(1-2):121-9. DOI: 10.1016/j.pain.2009.07.016. View

Sperber A, Bangdiwala S, Drossman D, Ghoshal U, Simren M, Tack J . Worldwide Prevalence and Burden of Functional Gastrointestinal Disorders, Results of Rome Foundation Global Study. Gastroenterology. 2020; 160(1):99-114.e3. DOI: 10.1053/j.gastro.2020.04.014. View

Steck N, Mueller K, Schemann M, Haller D . Bacterial proteases in IBD and IBS. Gut. 2011; 61(11):1610-8. DOI: 10.1136/gutjnl-2011-300775. View

Vergnolle N . Clinical relevance of proteinase activated receptors (pars) in the gut. Gut. 2005; 54(6):867-74. PMC: 1774539. DOI: 10.1136/gut.2004.048876. View

10.

Giardina S, Werner D, Pingle M, Bergstrom D, Arnold L, Barany F . A Novel, Nonpeptidic, Orally Active Bivalent Inhibitor of Human β-Tryptase. Pharmacology. 2018; 102(5-6):233-243. PMC: 6242772. DOI: 10.1159/000492078. View

11.

Fabisiak A, Sobocinska M, Kamysz E, Fichna J, Zielinska M . Antinociceptive potency of enkephalins and enkephalinase inhibitors in the mouse model of colorectal distension-proof-of-concept. Chem Biol Drug Des. 2018; 92(1):1387-1392. DOI: 10.1111/cbdd.13186. View

12.

Meleine M, Boudieu L, Gelot A, Muller E, Lashermes A, Matricon J . Comparative effects of α2δ-1 ligands in mouse models of colonic hypersensitivity. World J Gastroenterol. 2016; 22(31):7111-23. PMC: 4988313. DOI: 10.3748/wjg.v22.i31.7111. View

13.

Noble F, Turcaud S, Fournie-Zaluski M, Roques B . Repeated systemic administration of the mixed inhibitor of enkephalin-degrading enzymes, RB101, does not induce either antinociceptive tolerance or cross-tolerance with morphine. Eur J Pharmacol. 1992; 223(1):83-9. DOI: 10.1016/0014-2999(92)90821-k. View

14.

Vergnolle N . Protease inhibition as new therapeutic strategy for GI diseases. Gut. 2016; 65(7):1215-24. PMC: 4941139. DOI: 10.1136/gutjnl-2015-309147. View

15.

Wouters M, Balemans D, Van Wanrooy S, Dooley J, Cibert-Goton V, Alpizar Y . Histamine Receptor H1-Mediated Sensitization of TRPV1 Mediates Visceral Hypersensitivity and Symptoms in Patients With Irritable Bowel Syndrome. Gastroenterology. 2016; 150(4):875-87.e9. DOI: 10.1053/j.gastro.2015.12.034. View

16.

Tremaine W, Brzezinski A, Katz J, Wolf D, Fleming T, Mordenti J . Treatment of mildly to moderately active ulcerative colitis with a tryptase inhibitor (APC 2059): an open-label pilot study. Aliment Pharmacol Ther. 2002; 16(3):407-13. DOI: 10.1046/j.1365-2036.2002.01194.x. View

17.

Noble F, Soleilhac J, Turcaud S, Fournie-Zaluski M, Roques B . Inhibition of the enkephalin-metabolizing enzymes by the first systemically active mixed inhibitor prodrug RB 101 induces potent analgesic responses in mice and rats. J Pharmacol Exp Ther. 1992; 261(1):181-90. View

18.

Aguilera-Lizarraga J, Florens M, Viola M, Jain P, Decraecker L, Appeltans I . Local immune response to food antigens drives meal-induced abdominal pain. Nature. 2021; 590(7844):151-156. PMC: 7610810. DOI: 10.1038/s41586-020-03118-2. View

19.

Barbara G, Stanghellini V, De Giorgio R, Cremon C, Cottrell G, Santini D . Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology. 2004; 126(3):693-702. DOI: 10.1053/j.gastro.2003.11.055. View

20.

De Bruyn M, Ceuleers H, Hanning N, Berg M, De Man J, Hulpiau P . Proteolytic Cleavage of Bioactive Peptides and Protease-Activated Receptors in Acute and Post-Colitis. Int J Mol Sci. 2021; 22(19). PMC: 8509398. DOI: 10.3390/ijms221910711. View